English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Brigitte Schurcha, Abdul Al-Khodairyb,Ulf Berschc, Fiona Burkhardd, Daniel Engelere, Christophe Hugonnetf, Christian Kättererg, Jürgen Pannekh a Paraplegikerzentrum Uniklinik Balgrist, Zürich, b Clinique Romande de Réadaptation-suvacare, Sion, c Schweizer Paraplegiker-Zentrum, Nottwil, d Inselspital, Bern, e Kantonsspital, St. Gallen, fBulle, g REHAB, Basel, h Schweizer Paraplegiker-Zentrum, Nottwil SOC I É T É SAVANTE Forum Med Suisse 2009;9(14):284–285 284

Utilisation de la toxine botulinique de type A (BoNT-A) lors dune hyperactivité neurogène du détrusor

Utilisation de la toxine botulinique de type A (BoNT-A) lors dune hyperactivité neurogène du détrusor